ScreenerHero

CHRSCoherus BioSciences, Inc.

NAS · US · Healthcare · Biotechnology · coherus.com
1.420USD+6.77%Mkt Cap: 219.39M $P/E: —

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting gr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap219.39M $
Enterprise Value152.81M $
Revenue (TTM)50.94M $
Gross Profit28.36M $
Net Income (TTM)168.02M $
Revenue/Share0.3860 USD
Last Price1.420 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees144
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS19249H1032
Valuation
P/E (Trailing)—
P/E (Forward)-2.10
PEG—
EV/EBITDA-1.02
EV/Revenue3.00
P/S4.00
P/B3.35
EPS (TTM)-1.24
EPS (Forward)-0.63
52W Range
1.03025% of range2.616
52W High2.616 USD
52W Low1.030 USD
Profitability
Gross Margin67.24%
Oper. Margin-225.98%
EBITDA Margin-295.25%
Profit Margin398.43%
ROE275.39%
ROA65.04%
Growth
Revenue Growth39.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.51M $
CapEx (TTM)—
FCF Margin-314.42%
FCF Yield-73.00%
Net Debt-51.13M $
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity0.66
Current Ratio1.77
Quick Ratio1.58
Book Value/Sh0.3940 USD
Cash/Share0.6820 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.750 USD
Upside (mean)+445.8%
Target Range4.000 USD – 10.00 USD
$4.000+445.8% to mean$10.00
# Analysts4
Ownership
Shares Out.154.50M
Float135.60M
Insiders19.12%
Institutions37.41%
Short Interest
Short Ratio35.1d
Short % Float16.36%
Short % Out.15.88%
Shares Short24.53M
Short (prev mo.)25.98M
Technical
SMA 501.411 (+0.7%)
SMA 2001.570 (-9.6%)
Beta0.95
S&P 52W Chg18.16%
Avg Vol (30d)893.00K
Avg Vol (10d)1.49M
Technical Indicators
RSI (14)54.9
MACD-0.0520
MACD Signal-0.0585
MACD Hist.+0.0064
BB Upper1.580 USD
BB Middle1.340 USD
BB Lower1.099 USD
BB Width35.87%
ATR (14)0.1037 USD
Vol Ratio (20d)1.59x